Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations

1 Nov 2017

Abstract excerpt

Abstract Cancer drug screening in patient‐derived cells holds great promise for personalized oncology and drug discovery but lacks standardization. Whether cells are cultured as conventional monolayer or advanced, matrix‐dependent organoid cultures influences drug effects and thereby drug selection and clinical success. To precisely compare drug profiles in differently cultured primary cells, we developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to PARP inhibition in cancer therapy
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29180611
DOI: 10.15252/msb.20177697

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterationsPMID 29180611Read ↗

Resolving drug effects in patient-derived cancer cells links organoid responses to genome alterationsSemantic proximity Read ↗

Trellis Single-Cell Screening Reveals Stromal Regulation of Patient-Derived Organoid Drug ResponsesSemantic proximity Read ↗

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read ↗

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responsesSemantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

Targeting cancer drug resistance utilizing organoid technologySemantic proximity Read ↗

Patient‐derived organoid culture in epithelial ovarian cancers—Techniques, applications, and future perspectivesSemantic proximity Read ↗

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoidsSemantic proximity Read ↗

A Scalable 3D High-Content Imaging Protocol for Measuring a Drug Induced DNA Damage Response Using Immunofluorescent Subnuclear γH2AX Spots in Patient Derived Ovarian Cancer OrganoidsSemantic proximity Read ↗

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity Read ↗

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseSemantic proximity Read ↗

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.